Buy now: Trend is firmly bullish (stacked moving averages + expanding positive MACD) and fundamentals just printed a strong 2025/Q4.
Positioning/sentiment supports upside: Hedge funds are aggressively adding; options positioning is heavily call-skewed (very low put/call ratios).
Near-term setup is stretched: RSI is overbought and price is pressing resistance (26.47 area), so upside may come with brief consolidations—but for an impatient buyer, the data still favors owning rather than waiting.
Technical Analysis
Trend: Bullish (SMA_5 > SMA_20 > SMA_200) with momentum improving.
MACD: Histogram +0.103 and expanding → confirms bullish momentum.
RSI (6): 80.25 → overbought/extended in the very short term.
Key levels: Pivot 24.924 (important trend support). Resistance: R1 25.877 already cleared; next is R2 26.466 (price is currently ~26.28 post-market, close to this cap). Supports: S1 23.971, S2 23.382.
Pattern-based forward bias (provided): modest +0.98% next week expectation, but slightly negative next month (-0.88%) → suggests near-term strength may cool after the current run.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Extremely bullish skew.
Open Interest Put/Call = 0.10 (puts very light vs calls).
Volume Put/Call = 0.13 (today’s flow also call-dominant).
Participation: Today’s option volume 5,647 is ~45.78% of the 30D average (not a panic chase; more controlled participation).
Volatility: IV(30D) 30.17 vs HV 23.5; IV percentile 13.15 / IV rank 5.11 → implied vol is relatively low vs its own history (often supportive of call-buying/long setups).
Scale: Call OI 298,640 vs Put OI 29,649 → positioning remains decisively tilted toward upside.
Technical Summary
Sell
5
Buy
10
Positive Catalysts
2025/Q4 earnings strength is the main catalyst: strong growth in revenue, net income, and EPS supports a higher price floor.
Analyst target raises (clustered in January) reinforce improving fundamentals narrative and can pull incremental buyers in.
Management/leadership news: Appointment of a new Wealth Management CIO is a modest positive for strategy execution and client growth (not a major price catalyst on its own).
Neutral/Negative Catalysts
while sitting just below/near a key resistance zone (~26.
→ increases odds of a short-term stall.
Financial Performance
Latest quarter: 2025/Q4
Revenue: $810M, +23.66% YoY
Net Income: $257M, +63.69% YoY
EPS: $0.52, +79.31% YoY
Takeaway: Clear acceleration in profitability and EPS growth vs revenue growth → indicates improving operating leverage and/or better credit/expense dynamics into the quarter.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend (Jan 2026): Broad wave of price target increases after Q4 results, indicating improving confidence.
Bullish/positive stances: Barclays Overweight (PT 30), Stephens Overweight (PT 29), Raymond James Outperform (PT 27).
More cautious stances: Goldman Neutral (PT 27), Evercore In Line (PT 26), TD Cowen Hold (PT 27), Truist Hold (PT 27), DA Davidson Neutral (PT 27), Keefe Bruyette Market Perform (PT 25).
Wall Street pros: strong Q4 momentum, improving loan growth/C&I, operating leverage rebound potential, supportive 2026 tailwinds for regionals.
Wall Street cons: relative value debate (some prefer other banks), credit risk as the key uncertainty, and guidance execution (fee/lending assumptions) needs to hold.
Wall Street analysts forecast FHN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FHN is 26.25 USD with a low forecast of 23 USD and a high forecast of 28 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
Wall Street analysts forecast FHN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FHN is 26.25 USD with a low forecast of 23 USD and a high forecast of 28 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
9 Hold
0 Sell
Moderate Buy
Current: 25.840
Low
23
Averages
26.25
High
28
Current: 25.840
Low
23
Averages
26.25
High
28
UBS
Buy
maintain
$28 -> $29
AI Analysis
2026-02-04
New
Reason
UBS
Price Target
$28 -> $29
AI Analysis
2026-02-04
New
maintain
Buy
Reason
UBS raised the firm's price target on First Horizon (FHN) to $29 from $28 and keeps a Buy rating on the shares. Mid-cap banks have delivered strong results and avoided early Q4 credit concerns. Investor momentum into regional banks is expected to continue, supported by curve steepening, accelerating loan growth, and M&A activity such as Santander's (SAN) acquisition of Webster (WBS).
Barclays
NULL
to
Overweight
maintain
$28 -> $30
2026-01-16
Reason
Barclays
Price Target
$28 -> $30
2026-01-16
maintain
NULL
to
Overweight
Reason
Barclays raised the firm's price target on First Horizon to $30 from $28 and keeps an Overweight rating on the shares. The company reported "strong" Q4 results across the board and management is being conservative on its growth and net interest margin guidance, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FHN
